The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Inclusion Criteria: * Confirmed diagnosis of Cerebral Venous thrombosis (CVT), with or without intracranial haemorrhage. * Patients in the acute or sub-acute phase of CVT. * Completion of anticoagulation therapy for 5-15 days which has been administered until randomization; anticoagulation must include full-dose low molecular weight heparin or unfractionated heparin. * Eligibility for treatment with an oral anticoagulant. * Written informed consent. Exclusion Criteria: * Cerebral Venous thrombosis (CVT) associated with central nervous system infection or due to head trauma. * Thrombosed venous sinuses showed completely recanalized by MRV before randomisation. * Planned endovascular treatment for CVT or surgical treatment for other diseases. * Conditions associated with increased risk of bleeding. * History of symptomatic non-traumatic intracranial haemorrhage with increased risk of recurrence according to investigator's judgment. * Treatment with an antithrombotic regimen for an indication other than CVT and requiring continuation of that treatment for the original diagnosis. * Severe renal impairment(CrCL\<30mL/min). * Active liver disease (ALT≥ twice the upper limit of normal). * Preganancy, nursing or planning to become pregnant during the trial.